Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Visualizing DNA Repair Proteins with the FV3000 Confocal Microscope
February 11, 2019 Off

Visualizing DNA Repair Proteins with the FV3000 Confocal Microscope

By Dino Mustafić

The FV3000 microscope from Olympus has allowed Dr. JaeJin Kim and others in the Miller lab to generate DNA damage using laser-microirradiation and study DNA damage response factor behavior both in fixed and live cells.

Immunicium to treat cancer patients with its lead in-development-product, ILIAD
February 11, 2019 Off

Immunicium to treat cancer patients with its lead in-development-product, ILIAD

By Dino Mustafić

Immunicum has treated the first patient in the Phase Ib/II clinical trial of its lead product in development, ilixadencel (ILIAD), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.

Basilea nets milestone payment from Pfizer for Cresemba sales in Europe
February 8, 2019 Off

Basilea nets milestone payment from Pfizer for Cresemba sales in Europe

By Dino Mustafić

Basilea Pharmaceutica cahsed $5 million from Pfizer’s milestone payment triggered for selling of the antifungal Cresemba in Europe..

Pulmatrix to start phase two testing Pulmazole in certain asthma patients
February 7, 2019 Off

Pulmatrix to start phase two testing Pulmazole in certain asthma patients

By Dino Mustafić

Pulmatrix can now begin to test in second phase its anti-fungal drug itraconaole inhaled iSPERSE formulation, to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma, after the US FDA approved the company’s Investigational New Drug (IND) Application.

Pharmazz’s PMZ-1620 could become the first-in-class therapy to treat cerebral ischemic stroke
February 7, 2019 Off

Pharmazz’s PMZ-1620 could become the first-in-class therapy to treat cerebral ischemic stroke

By Dino Mustafić

Pharmazz’s PMZ-1620 could become the first-in-class therapy to treat cerebral ischemic stroke, the company said in a statement, through an endothelin (ETB receptor) based mechanism of action, of anti-apoptosis and stimulation of hidden stem cells to repair the damaged brain by formation of new neurons and blood vessels.

Innovent can test its protein in patients with hemaological and advanced solid tumors
February 7, 2019 Off

Innovent can test its protein in patients with hemaological and advanced solid tumors

By Dino Mustafić

Innovent Biologics got approval from the National Medical Products Administration (NMPA) to start clinical trials for its IND application for IBI318, a recombinant fully human bispecific antibody targeting programmed cell death protein 1 (PD-1) and an undisclosed target for a tumor-associated antigen (TAA), in patients with hematological and advanced solid tumors.

February 7, 2019 Off

NanoViricides names new Executive leader amid CEO resignation for personal reasons

By Dino Mustafić

NanoViricides confirmed in a statement that its CEO, Dr. Irach Taraporewala has resigned effective January 31, 2019, for personal reasons, and will continue as a Consultant to help the company with its regulatory advance as needed. The Board has promoted current President and Board Chairman, Dr. Anil Diwan, to Executive Chairman.

Innate Pharma gets faster development of its Sézary syndrome treatment
January 29, 2019 Off

Innate Pharma gets faster development of its Sézary syndrome treatment

By Dino Mustafić

Innate Pharma will speed up the development of its anti-KIR3DL2 antibody, to treat T-cell lymphoma, as it has been fast tracked by the US FDA, the company said Tuesday.

Novartis’ Cosentyx effective for psoriasis patients, placebo isn’t
January 28, 2019 Off

Novartis’ Cosentyx effective for psoriasis patients, placebo isn’t

By Dino Mustafić

Patients with certain plaque psoriasis treated with 300mg of Cosentyx for only four weeks reported in a questionnaire improvements in life quality, novartis said Monday.

Imbruvica approved combination therapy with rituximab in USA
January 28, 2019 Off

Imbruvica approved combination therapy with rituximab in USA

By Dino Mustafić

U.S. Food and Drug Administration (FDA) approved AbbVie’s Imruvica (ibrutinib) combined rituximab (Rituxan) for treating adult patients with Waldenström’s macroglobulinemia (WM).

Posts pagination

Previous 1 … 3,365 3,366 3,367 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine